Dendritic Cell Vaccine for Leptomeningeal Disease in Breast Cancer
This study is testing a treatment called Dendritic Cell Vaccine (DCV) for people with breast cancer that has spread to the fluid around the brain and spinal cord (leptomeningeal disease, or LMD). Specifically, it's for those with triple-negative breast cancer (TNBC) or HER2-positive breast cancer. The main goal is to find the highest dose of DCV that can be given safely. The vaccine is given directly into the spinal fluid (intrathecal). To join, you must have a confirmed diagnosis of TNBC or HER2-positive breast cancer and LMD, with cancer cells found in your spinal fluid. The study is currently unclear on its recruitment status and plans to enroll about 15 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to find the maximum tolerated dose of the Dendritic Cell Vaccine.
- What's involved
- You would receive the Dendritic Cell Vaccine (DCV) directly into your spinal fluid once a week. This procedure takes about 5-10 minutes.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main safety measurement for the vaccine dose will be assessed for up to 12 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05809752
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatmentH. Lee Moffitt Cancer Center and Research InstituteInvestigator-initiated
~15 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:Dendritic Cell Vaccine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine
Measured over Up to 12 weeks
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Peter A Forsyth, MD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically or cytologically confirmed diagnosis of TNBC or HER2+BC per ASCO/CAP guidelines . A tumor can be considered a TNBC if the ER or PR is \<10%.
Trial participants must have a diagnosis of LMD. They must have the presence of malignant cells in the CSF (CSF+; note now cytology is considered diagnostic of LMD if the cytology is read as positive or suspicious; OR characteristic radiographic abnormalities (see below) of LMD). Signs and symptoms of LMD in and of themselves are not sufficient for inclusion.
Patients must have an Eastern Cooperative Oncology Group performance scale of ≤ 3.
Coincident Brain or Spinal cord metastases are allowed if these are stable and do not require local therapy at the time of enrollment. Individuals with previously treated stable Brain metastases are eligible to participate.
Stereotactic Radiosurgery (SRS) and/or prior radiotherapy is permitted \> 2 weeks prior to initial Dendritic Cell (DC) vaccine dose. A follow up brain MRI should be obtained prior to DC vaccine to determine stability of the lesions. An interval of at least 4 weeks after the end of whole brain radiation or for any surgical resection of brain lesions is permitted.
Life expectancy of ≥ 8 weeks.
Demonstrate adequate organ function as defined in protocol. All screening labs should be performed with 14 days of treatment initiation.
Provision of signed and dated informed consent form.
Corticosteroids at doses equivalent to 8 mg dexamethasone daily for symptom control are acceptable. This should be minimized wherever possible.
Exclusion
Patients with systemic disease are eligible and will be managed as detailed in Section 6.3.1.
Pregnancy test: negative serum or urine pregnancy test at screening for women of childbearing potential. Must be repeated once-monthly during treatment. Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 90 days after last treatment administration, if the risk of conception exists.
The patient has an Ommaya reservoir or equivalent device which allows routine access to CSF and administration of DC1s.
Receiving other treatments specifically administered to treat LMD within the last 2 weeks or 5 half-lives of the agent, whichever is less. However, all other treatments to control systemic disease or bulk CNS disease will be eligible, provided the therapy is not a phase I agent, an agent which significantly and unequivocally penetrates the CSF (e.g., high-dose methotrexate, thiotepa, high-dose ara-C) per PI discretion.
The use of any immunotherapy within the last four weeks.
Patients with a ventriculoperitoneal or ventriculoatrial shunt must have an on/off device in their shunt systems to be eligible for the study. Patients must be able to tolerate shunt closure for \~4 hours without development of clinical signs of increased intracranial pressure. Patients unable to tolerate shunt closure for \~4 hours will not be eligible for the study.
Unable or unwilling to have a contrast-enhanced brain MRI.
Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin,squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
Has an active infection requiring systemic therapy which in the opinion of the investigator will increase the risk to the patient.
Had major surgical procedure, or significant traumatic injury within two weeks. Ommaya placement is allowed.
Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment.
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1, 2 antibodies). Testing is not mandatory.
Has known active or chronic hepatitis B (HBV) or hepatitis C virus (HCV). Testing is not mandatory.
ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.
Other severe acute or chronic medical conditions or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Has received a blood transfusion in the two weeks prior to leukapheresis.
Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Current COVID vaccines are not live vaccines.
What this trial measures
- Maximum Tolerated Dose of Intrathecal Dendritic Cell VaccineUp to 12 weeks
Maximum tolerated dose of intrathecal dendritic cell vaccine is defined as the highest dose of vaccine that does not cause undesirable side effects/dose limiting toxicity (DLT). To evaluate safety, the study team will monitor toxicities continuously and the study will be halted if an excessive number of toxicities are encountered.